Practice Tips From the Updated Helicobacter pylori Treatment Guidelines

Area of Science:

• Gastroenterology
• Infectious Diseases
• Clinical Practice Guidelines

Background:

• The American College of Gastroenterology (ACG) has released updated guidelines for managing Helicobacter pylori (H pylori) infection in 2024.
• These new guidelines replace the 2017 recommendations, incorporating significant advancements in treatment and understanding of antimicrobial resistance.
• Antimicrobial resistance to common H pylori treatments like clarithromycin, levofloxacin, and metronidazole now exceeds 30%.

Purpose of the Study:

• To summarize the key clinical updates in the 2024 ACG H pylori management guidelines.
• To highlight the differences between the 2024 and previous 2017 guidelines.
• To provide a digestible overview for gastroenterologists and clinicians treating H pylori infections.

Main Methods:

• Review and synthesis of the 2024 American College of Gastroenterology guidelines for H pylori infection.
• Comparison of the updated recommendations with the previous 2017 guidelines.
• Focus on changes in screening, first-line treatment selection, and antimicrobial susceptibility testing.

Main Results:

• The 2024 guidelines introduce new recommendations for H pylori screening practices.
• Updated guidance is provided on selecting optimal first-line treatment regimens, considering newly approved options.
• Emphasis is placed on the use of antimicrobial susceptibility testing for refractory H pylori infections.

Conclusions:

• The 2024 ACG guidelines represent a significant update in H pylori management, reflecting new treatment options and rising resistance.
• Clinicians should familiarize themselves with these changes to optimize patient care and treatment outcomes.
• The updated guidelines aim to improve the efficacy of H pylori eradication strategies in clinical practice.